Human Heme-Oncology Peripheral Blood Mononuclear Cells

Description

Human Heme-Oncology Peripheral Blood Mononuclear Cells (PBMCs) are a type of mononuclear cell population derived from peripheral blood, mainly including lymphocytes (T cells, B cells, NK cells) and monocytes. These cells were derived from patients with hematologic oncology conditions (e.g., leukemia, lymphoma, myeloma). They display round mononuclear morphology and grow in suspension with minimal or no substrate adhesion. PBMCs play an important role in immune regulation. T cells and B cells mediate adaptive immunity, including recognizing pathogens and producing antibodies. NK cells perform natural killing functions, while monocytes can differentiate into macrophages or dendritic cells, which participate in antigen presentation and inflammation regulation. PBMCs from heme-oncology donors exhibit disease-specific markers (e.g., CD19⁺ in B-cell malignancies, CD33⁺ in AML) and retain functional properties including cytokine secretion and tumor reactivity. These cells are ideal for investigating leukemia, lymphoma, multiple myeloma, and CAR-T/immunotherapy development. These PBMCs enable detailed immune profiling in heme-oncology, facilitating analysis of T cell subsets in heme-oncology, the B cell role in heme-oncology, cytokine expression in heme-oncology, and identification of key heme-oncology blood biomarkers.